** Shares of drug developer Altimmune ALT.O fall 8.9% to $3.89
** Co reports Q4 loss of 27 cents/shr vs analysts' average estimate of 24 cents/shr - data compiled by LSEG
** Says Q4 revenue was $26,000 vs estimate of $700,000
** Shares down 50% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.